๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II Study of Bryostatin 1 in Patients with Relapsed Multiple Myeloma

โœ Scribed by Mary L. Varterasian; Pamela A. Pemberton; Kim Hulburd; Dorothy H. Rodriguez; Anthony Murgo; Ayad M. Al-Katib

Book ID
110294274
Publisher
Springer US
Year
2001
Tongue
English
Weight
42 KB
Volume
19
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II trial of temsirolimus in patien
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
โœ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat

Phase II trial of amsacrine in patients
Phase II trial of amsacrine in patients with multiple myeloma
โœ Greipp, Philip R. ;Coleman, Morton ;Anderson, Keaven ;McIntyre, O. Ross ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 239 KB

Seventy-four previously treated patients with multiple myeloma were treated with Amsacrine (m-AMSA) 120 mg/m2 every 3 weeks. A good response was observed in two patients (3%), and improvement was seen in three patients (4%). Severe toxicity was observed in 33% of patients who received three or more